Pretreatment ADC Histogram Analysis as a Prognostic Imaging Biomarker for Patients with Recurrent Glioblastoma Treated with Bevacizumab: A Systematic Review and Meta-analysis
- 20 January 2022
- journal article
- review article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43 (2) , 202-206
Abstract
BACKGROUND: The mean ADC value of the lower Gaussian curve (ADCL) derived from the bi-Gaussian curve-fitting histogram analysis has been reported as a predictive/prognostic imaging biomarker in patients with recurrent glioblastoma treated with bevacizumab; however, its systematic summary has been lacking. PURPOSE: We applied a systematic review and meta-analysis to investigate the predictive/prognostic performance of ADCL in patients with recurrent glioblastoma treated with bevacizumab. DATA SOURCES: We performed a literature search using PubMed, Scopus, and EMBASE. STUDY SELECTION: A total of 1344 abstracts were screened, of which 83 articles were considered potentially relevant. Data were finally extracted from 6 studies including 578 patients. DATA ANALYSIS: Forest plots were generated to illustrate the hazard ratios of overall survival and progression-free survival. The heterogeneity across the studies was assessed using the Cochrane Q test and I2 values. DATA SYNTHESIS: The pooled hazard ratios for overall survival and progression-free survival in patients with an ADCL lower than the cutoff values were 1.89 (95% CI, 1.53–2.31) and 1.98 (95% CI, 1.54–2.55) with low heterogeneity among the studies. Subgroup analysis of the bevacizumab-free cohort showed a pooled hazard ratio for overall survival of 1.20 (95% CI, 1.08–1.34) with low heterogeneity. LIMITATIONS: The conclusions are limited by the difference in the definition of recurrence among the included studies. CONCLUSIONS: This systematic review with meta-analysis supports the prognostic value of ADCL in patients with recurrent glioblastoma treated with bevacizumab, with a low ADCL demonstrating decreased overall survival and progression-free survival. On the other hand, the predictive role of ADCL for bevacizumab treatment was not confirmed.Keywords
This publication has 32 references indexed in Scilit:
- Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and IrinotecanPLOS ONE, 2014
- A Randomized Trial of Bevacizumab for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic TherapyPLOS ONE, 2013
- Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyJournal of Neuro-Oncology, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated GlioblastomaAmerican Journal of Neuroradiology, 2011
- Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant GliomaCA: A Cancer Journal for Clinicians, 2010
- Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2New England Journal of Medicine, 2009
- Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab TreatmentRadiology, 2009